Are INM insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies INM leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / INM / insiders

PTN (35) BFRG (32) MBRX (34) CMMB (31) ⌘ Pro Terminal →

InMed Pharmaceuticals Inc. (INM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.60 -1.54% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.59

InMed Pharmaceuticals Inc. (INM) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $8.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, InMed Pharmaceuticals Inc. (NASDAQ: INM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.60 (-1.54% 1D, market cap $8.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, INM ranks #317 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INM compare to PTN and BFRG in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INM carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 34.5%, and ROIC of -35.0%. By comparison, PTN (Palatin Technologies Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M) and BFRG (Bullfrog AI Holdings Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $9.0M). Among the 5-stock peer group, INM leads on earnings multiple (N/A) while INM leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INM?

▼

Per INM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001728328), InMed Pharmaceuticals Inc. generated $4.9M in revenue (+7.5% YoY), -$8.2M in net income, and -$8.1M in free cash flow against $11.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.59 (-0.47%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INM)Realized 20D OHLCV Swing Band: ±11%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY INM SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (28% of score)

20D Institutional Volume Accumulation (±11% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime × Technicals: 59% of 52W Range • RSI-14 at 67 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.33+0.8% Next Q

Q2 (-2Q)

Grade D$1.34+18.7% Next Q

Q3 (-1Q)

Grade D$1.59+0.6% Next Q

Current

Grade D$1.60-5.9% Hist 90D α

Trajectory: E (39) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INM currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.39) and Max Pain ($1.68) forces dealer call-delta covering toward $2.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INM Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

INM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (INM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on INM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INM)

✓Walkthrough of INM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +113.33%⚡ TESTING RESISTANCE

2026-11-03O $1.62H $1.62L $1.60C $1.60VOL 36.7K

RES: $1.68SUP: $1.14SMA50: $1.39SMA200: $1.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INM Butterfly Map → + Track INM →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +7.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INM)

Health Care Rank #317 of 1015 ⚔️ PTN vs INM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INM vs. PTN, BFRG, MBRX, CMMB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, InMed Pharmaceuticals Inc. (INM) ranks #317 by composite RQD confidence (47/100, grade D) and #903 by equity capitalization ($8.8M). Within this direct 5-issuer industry benchmark cohort, INM leads on earnings valuation at N/A trailing P/E, while INM leads on capital efficiency and profitability with -35.0% ROIC and 34.5% gross margin. INM currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INM ACTIVE InMed Pharmaceuticals Inc.	D	47/100	—	34.5%	-35.0%	-1.54%	$8.8M	Benchmark Subject
PTN Palatin Technologies Inc.	D-	35/100	—	—	-35.0%	+1.42%	$8.9M	/ptn-vs-inm →
BFRG Bullfrog AI Holdings Inc.	E	32/100	—	18.8%	-35.0%	-3.62%	$9.0M	/bfrg-vs-inm →
MBRX Moleculin Biotech Inc.	E	34/100	—	—	-35.0%	-9.40%	$8.3M	/mbrx-vs-inm →
CMMB Chemomab Therapeutics Ltd.	E	31/100	—	—	-35.0%	+6.42%	$9.3M	/cmmb-vs-inm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001728328 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), InMed Pharmaceuticals Inc. (INM) reported GAAP revenue of $4.9M (+7.5% vs. FY2024 revenue of $4.6M , and +19.5% cumulative change since FY2023) , GAAP net income of -$8.2M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-15.8% YoY). On the balance sheet, INM closed FY2025 with $11.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$4.9M	-$8.2M	-$8.1M	-$8.1M	$11.2M	—
FY2024 (FY)	2024-06-30	$4.6M	-$7.7M	-$7.0M	-$7.0M	$8.5M	—
FY2023 (FY)	2023-06-30	$4.1M	-$7.9M	-$7.3M	-$7.3M	—	—

3. INM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INM compare to PTN and BFRG in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INM?

Where is INM trading relative to its 50-day, 200-day, and 52-week technical levels?

INM last traded at $1.60 (-1.54% on volume of 36,687 shares), positioning the stock +15.11% above its 50-day simple moving average ($1.39) and +32.23% above its 200-day simple moving average ($1.21). Across its 52-week range of $0.57 to $2.33, INM sits at the 58.5% percentile with a 14-day RSI of 67.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.0% ($1.42 to $1.78).

Direct Sub-Reports: INM RQD Cockpit INM 12M Forecast INM Earnings & Move INM Dividends & DRIP INM Insiders & 13F INM Whale Options INM Profit Sankey INM News & Why

ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

INM — InMed Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

InMed Pharmaceuticals Inc. (INM) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.60 (-1.54% 1D, market capitalization $8.8M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 34.5%, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (13/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

InMed Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the market data, gross margin is 34.5%, operating margin is 0%, and net margin is -60%. FY 2025 revenue was $4.9M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), InMed Pharmaceuticals Inc. (INM) reported $4.9M in annual revenue (up from $4.6M in FY2024, +7.5% YoY) and -$8.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.1M revenue, -$7.9M net income) through FY2025, INM scaled operating cash flow to -$8.1M and free cash flow to -$8.1M, backed by $11.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 13/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $0.57 – $2.33 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the provided data.

Key Question #1: Can INM sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $4.9M and free cash flow of -$8.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is INM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

INM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for InMed Pharmaceuticals Inc. (INM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INM Debate Forum (3) ↓

🟢 CATALYST TradingView • 1d ago

InMed Pharmaceuticals Inc. (INM) Sets Nov. 5 CVR Record Date, Pending Shareholder Vote

TradingView report covering InMed Pharmaceuticals Inc. (INM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

At $1.32–$1.33 a share, ADAR1 funds buy 9,569 shares of InMed Pharmaceuticals (INM).

Stock Titan report covering InMed Pharmaceuticals Inc. (INM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TMX Newsfile • 1d ago

InMed Announces CVR Distribution Record Date in Connection with Proposed Merger

TMX Newsfile report covering InMed Pharmaceuticals Inc. (INM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine Media • 1d ago

ADAR1 Capital Management Acquires 4 Shares of InMed Pharmaceuticals at $1.32 Each

Kalkine Media report covering InMed Pharmaceuticals Inc. (INM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

At $1.32 each, ADAR1 funds buy 4 shares of InMed Pharmaceuticals (INM).

Stock Titan report covering InMed Pharmaceuticals Inc. (INM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Nov. 5 determines which InMed shareholders may qualify for rights to future payments.

Stock Titan report covering InMed Pharmaceuticals Inc. (INM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Funds hold 943,668 InMed Pharmaceuticals (INM) shares, with voting power shared by two reporting persons.

Stock Titan report covering InMed Pharmaceuticals Inc. (INM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 1d ago

Buying on the cutoff date isn't expected to qualify for InMed (INM)'s proposed payment rights.

Stock Titan report covering InMed Pharmaceuticals Inc. (INM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INM Bull vs. Bear Conversation Board — What's Your Call at $1.60?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INM 🐻 33% BEARISH CONVICTION

AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $2.03 (+26.9%)

📌 Pinned Debate

Reported cash rose to $7.0M in FY 2025 from $3.4M in FY 2024 while revenue grew from $4.1M to $4.9M across the reported periods.

Reported cash rose to $7.0M in FY 2025 from $3.4M in FY 2024 while revenue grew from $4.1M to $4.9M across the reported periods.. When you look under the hood at INM, Fundamental Cash Engine is 6/20 with 34.5% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (13/20) has been quietly accumulating below $2.33. My 12M target is $2.03.

SectorRotator 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (34.5%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.31 (-18.1%)

Spot @ $1.60

ROIC of -35%, net margin of -60%, and FCF yield of 0% indicate the business is not currently generating returns on capital or free cash

Here is the bear case nobody on the bull side wants to address on INM: ROIC of -35%, net margin of -60%, and FCF yield of 0% indicate the business is not currently generating returns on capital or free cash flow.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.